Business Context and Reporting Period
Company: Launch One Acquisition Corp. (LPAA)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Launch One is a Cayman Islands exempted company formed as a Special Purpose Acquisition Company (SPAC) to effect a business combination with one or more target businesses. The Company has no operating history and generates no operating revenue. Its primary activity is searching for and consummating an initial business combination.
Key Status Update: On January 30, 2026, the Company mutually terminated its Business Combination Agreement with Minovia Therapeutics Ltd. The Company is currently seeking alternative targets to consummate a business combination by its deadline of July 15, 2026.
Key Financial Metrics
| Metric | Year Ended Dec 31, 2025 | Period Ended Dec 31, 2024 |
|---|---|---|
| Net Income | $8,309,154 | $5,129,519 |
| Trust Account Balance | $245,449,353 | $235,529,521 |
| Redemption Price (per share) | ~$10.67 | ~$10.24 |
| Cash Outside Trust Account | $30,146 | $850,338 |
| Working Capital | ($609,961) Deficit | $947,121 |
| General & Administrative Expenses | $1,611,081 | $400,002 |
| Interest Income (Trust Account) | $9,919,832 | $5,404,164 |
Debt and Liquidity: As of December 31, 2025, the Company had no outstanding borrowings under Working Capital Loans. However, the Company reported a working capital deficit of $609,961. On March 20, 2026 (subsequent to year-end), the Company entered into a Working Capital Promissory Note allowing for loans up to $1,000,000 from the Sponsor to fund operations.
Material Changes vs. Prior Period
- Trust Account Growth: The Trust Account balance increased by approximately $9.9 million, driven by interest income earned on marketable securities and cash held in the account.
- Expense Increase: General and administrative expenses increased significantly from $400,002 in 2024 to $1,611,081 in 2025, reflecting costs associated with the search for a business combination and the terminated Minovia transaction.
- Liquidity Deterioration: Cash held outside the Trust Account decreased from $850,338 to $30,146, resulting in a shift from positive working capital to a working capital deficit.
- Transaction Termination: The Company terminated its proposed business combination with Minovia Therapeutics Ltd. in January 2026, a material change from the prior period where the agreement was active.
Outlook, Risks, and Contingencies
Outlook and Guidance: The Company must consummate an initial business combination by July 15, 2026. If no combination is completed by this date, the Company will cease operations, redeem Public Shares from the Trust Account, and liquidate. Management is actively seeking alternative targets following the Minovia termination.
Going Concern: The filing includes a "substantial doubt" regarding the Company's ability to continue as a going concern due to limited liquidity outside the Trust Account and the mandatory liquidation date. Management's plan to address this is to consummate a business combination.
Risks and Contingencies:
- Extension Risk: If the Company cannot complete a deal by July 2026, it may seek shareholder approval to extend the deadline, which would require shareholders to vote and potentially redeem shares, reducing the Trust Account balance.
- Financing Risk: The Company may need additional financing to complete a transaction. While a new Working Capital Note was secured in March 2026, there is no assurance that further financing will be available on acceptable terms.
- Geopolitical Risks: The filing highlights risks related to global conflicts (Ukraine, Middle East) that could disrupt capital markets and affect the ability to find or complete a transaction.
- Trust Account Claims: While the Sponsor has agreed to indemnify the Trust Account against certain third-party claims, there is no guarantee the Sponsor has sufficient assets to satisfy such obligations if claims arise.
Investor Verification Checklist
- Extension Timeline: Verify if the Company has filed a proxy statement to extend the July 15, 2026, combination deadline.
- Working Capital Sufficiency: Confirm the status of the March 2026 Working Capital Note and whether the initial $500,000 tranche has been funded to cover the current cash deficit.
- Redemption Levels: Monitor the redemption price per share ($10.67 as of year-end) and any potential dilution or reduction in the Trust Account due to taxes or extension redemptions.
- Target Pipeline: Assess the Company's progress in identifying a new target business following the termination of the Minovia agreement.
- Deferred Fee: Note the $10,950,000 deferred underwriting fee payable only upon the successful completion of a business combination.